VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Better fitness was linked to healthier brain structure, but not better memory

Researchers studying 353 cognitively unimpaired adults aged 60 to 94 found that higher muscular capacity was associated with lower basal ganglia perivascular space volume, while greater aerobic fitness was associated with greater gray matter volume and medial temporal lobe thickness. Fitness was not directly associated with global cognition or episodic memory, and evidence for cognitive reserve was limited, although VO₂max explained additional variation in delayed verbal memory beyond tau burden.

18 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Capillaries drive new collateral artery formation after heart blockage

New research in mice challenges a long-standing view of how the heart builds backup blood vessels after a coronary artery blockage, showing that new collateral arteries arise primarily from capillaries rather than existing arteries.

20 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Cosmetic microneedles deliver actives where creams struggle

This review shows how microneedle-based cosmetic systems bypass the stratum corneum to deliver poorly penetrating actives, including peptides, retinoids, vitamins, niacinamide, hyaluronic acid, and hair-growth compounds, into viable skin layers.

8 Jul 2026

New spatially resolved transcriptomic map reveals how bone and muscle cells communicate

A new study generated one of the most comprehensive spatially resolved transcriptomic maps of cellular communication between bone and skeletal muscle in a young mouse.

6 Jul 2026

Review explores complex associations between sleep apnea and lung cancer

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent hypoxia and sleep fragmentation, which may contribute to lung cancer development and progression.

29 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Hyperbaric oxygen therapy shows dual effects in glioblastoma treatment

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to its therapy resistance.

23 Apr 2026

Novel microneedle patch accelerates healing of chronic diabetic wounds using light

Researchers from Nanjing Drum Tower Hospital, Southeast University, and Wenzhou Medical University have developed a novel microneedle patch that combines MXene hydrogel with nitric oxide (NO) and hypoxia-inducible factor-1α (HIF-1α) plasmid for enhanced diabetic wound treatment.

10 Mar 2026

Armored CAR T cells overcome tumor defenses in solid cancers

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block their attack and fuel tumor growth.

4 Mar 2026

Distinct gut toxicity patterns emerge with targeted cancer treatments

A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection."

20 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Can hot baths lower high blood pressure?

A review highlights hot water immersion's potential in lowering blood pressure, emphasizing it as an adjunct therapy alongside traditional treatments.

12 Feb 2026

Transcription factor HOXD13 drives melanoma growth and immune evasion

A molecule that helps regulate gene activity has also been shown to drive skin cancer growth and tumors' ability to evade attack by the body's immune system, a new study shows.

11 Feb 2026

Tear biosensor detects diabetic retinopathy biomarkers for early diagnosis

Tear fluid is emerging as an attractive source of diagnostic information because it can be collected easily and non-invasively.

9 Feb 2026

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor Microenvironment Promotes Sorafenib Resistance in Hepatocellular Carcinoma via the 14-3-3η-Modified Tumor-Associated Proteome" in the Chinese Medical Journal.

23 Jan 2026

Pitavastatin shows pomise in overcoming chemotherapy resistance in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.

7 Jan 2026

Remodeling the tumor microenvironment to unlock CAR-T cell potential

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME).

22 Dec 2025